MedTrace Logo

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

NCT03641755 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-02-23

No results posted yet for this study

Summary

This research study is studying a combination of drugs as a possible treatment for breast cancer with a BRCA mutation.

The interventions involved in this study are:

* Sapacitabine (CYC682)
* Olaparib (Lynparza™)

Conditions

Interventions

DRUG

Sapacitabine

Sapacitabine may help to stop the growth of some types of cancers

DRUG

Olaparib

Olaparib is an inhibitor of PARP (poly \[adenosine diphosphate-ribose\] polymerase), which means that it stops PARP from working

Sponsors & Collaborators

Principal Investigators

  • Filipa Lynce, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2022-04-27
Completion
2026-10-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03641755 on ClinicalTrials.gov